Sulphonylurea‐induced hypoglycaemia in type 2 diabetes mellitus: a review

Fertig BJ, 1995, Diabetes in America,, 519

Jennings AM, 1989, Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents, Diabetes Care, 18, 163

Berger W., 1985, Incidence of severe side effects during therapy with sulfonylureas and biguanides, Horm Metab Res, 17, 111

10.1056/NEJM198911023211805

UK & Prospective Diabetes Study (UKPDS) Group., 1998, Intensive blood‐glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet, 352, 837, 10.1016/S0140-6736(98)07019-6

10.1001/archinte.1997.00440360095010

Seltzer HS., 1989, Drug‐induced hypoglycemia: a review of 1418 cases, Endocrinol Metab Clin, 18, 163, 10.1016/S0889-8529(18)30395-5

10.1016/S0895-4356(97)00024-3

10.1111/j.1532-5415.1996.tb03729.x

10.1001/jama.279.2.137

Anderson Jh, 1997, Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non‐insulin dependent diabetes mellitus, Arch Intl Med, 157, 1249, 10.1001/archinte.1997.00440320157015

Amiel SA, 1987, Rate of glucose fall does not affect counterregulatory hormone response to hypoglycemia in normal and diabetic humans, Diabetes, 36, 518, 10.2337/diab.36.4.518

10.2337/diab.37.7.901

10.2337/diacare.21.8.1330

10.2337/diab.37.6.736

10.2165/00002018-199411040-00002

Huupponen R., 1988, Significance ofsulin receptors in the actions of sulfonylurea drug, Ann Clin Res, 20, 373

Groop GM, 1987, Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects, Diabetes, 36, 1320, 10.2337/diab.36.11.1320

10.1016/S0196-0644(98)70239-2

10.1016/1056-8727(94)90044-2

Rosskamp R, 1996, Clinical profile of the novel sulfonylurea glimepiride, Diab Res Clin Pract, 31, S33, 10.1016/0168-8227(96)01228-4

10.1152/ajpendo.1993.264.2.E149

10.1056/NEJM198806093182302

10.1172/JCI112884

Mitrakou A, 1991, Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms and cerebral dysfunction, Am J Physiol, 260, E67

10.1007/BF00401425

10.1093/ageing/20.6.404

10.1210/jc.78.6.1341

10.2337/diab.41.6.671

10.2337/diab.32.11.1055

10.2337/diab.43.3.403

10.1172/JCI111359

10.1056/NEJM197412122912404

10.1002/j.1875-9114.1998.tb03137.x

10.2337/diacare.21.11.1897

10.1002/j.1875-9114.1996.tb02997.x

Anonymous., 1999, Physician’s Desk Reference. Montvale, NJ., 667

10.1056/NEJM199508313330902

10.1016/S0140-6736(98)07037-8

10.7326/0003-4819-130-5-199903020-00002

10.2337/diacare.21.9.1462

10.1056/NEJM199803263381303

10.1056/NEJM199803263381302